Increased intensity lymphodepletion and adoptive immunotherapy - How far can we go?

Pawel Muranski, Andrea Boni, Claudia Wrzesinski, Deborah E. Citrin, Steven A. Rosenberg, Richard Childs, Nicholas P. Restifo

Research output: Contribution to journalArticle

Abstract

In a recent clinical trial involving patients with metastatic melanoma, immunosuppressive conditioning with fludarabine and cyclophosphamide resulted in a 50% response rate in robust long-term persistence of adoptively transferred T cells. Experimental findings indicate that lymphodepletion prior to adoptive transfer of tumor-specific T lymphocytes plays a key role in enhancing treatment efficacy by eliminating regulatory T cells and competing elements of the immune system ('cytokine sinks'). Newly emerging animal data suggest that more profound lymphoablative conditioning with autologous hematopoetic stem-cell rescue might further enhance treatment results. Here we review recent advances in adoptive immunotherapy of solid tumors and discuss the rationale for lymphodepleting conditioning. We also address safety issues associated with translating experimental animal results of total lymphoid ablation into clinical practice.

Original languageEnglish (US)
Pages (from-to)668-681
Number of pages14
JournalNature Clinical Practice Oncology
Volume3
Issue number12
DOIs
StatePublished - Dec 2006
Externally publishedYes

Fingerprint

Adoptive Immunotherapy
T-Lymphocytes
Adoptive Transfer
Regulatory T-Lymphocytes
Immunosuppressive Agents
Cyclophosphamide
Immune System
Melanoma
Neoplasms
Stem Cells
Clinical Trials
Cytokines
Safety
Therapeutics
fludarabine

ASJC Scopus subject areas

  • Oncology

Cite this

Muranski, P., Boni, A., Wrzesinski, C., Citrin, D. E., Rosenberg, S. A., Childs, R., & Restifo, N. P. (2006). Increased intensity lymphodepletion and adoptive immunotherapy - How far can we go? Nature Clinical Practice Oncology, 3(12), 668-681. https://doi.org/10.1038/ncponc0666

Increased intensity lymphodepletion and adoptive immunotherapy - How far can we go? / Muranski, Pawel; Boni, Andrea; Wrzesinski, Claudia; Citrin, Deborah E.; Rosenberg, Steven A.; Childs, Richard; Restifo, Nicholas P.

In: Nature Clinical Practice Oncology, Vol. 3, No. 12, 12.2006, p. 668-681.

Research output: Contribution to journalArticle

Muranski, P, Boni, A, Wrzesinski, C, Citrin, DE, Rosenberg, SA, Childs, R & Restifo, NP 2006, 'Increased intensity lymphodepletion and adoptive immunotherapy - How far can we go?', Nature Clinical Practice Oncology, vol. 3, no. 12, pp. 668-681. https://doi.org/10.1038/ncponc0666
Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R et al. Increased intensity lymphodepletion and adoptive immunotherapy - How far can we go? Nature Clinical Practice Oncology. 2006 Dec;3(12):668-681. https://doi.org/10.1038/ncponc0666
Muranski, Pawel ; Boni, Andrea ; Wrzesinski, Claudia ; Citrin, Deborah E. ; Rosenberg, Steven A. ; Childs, Richard ; Restifo, Nicholas P. / Increased intensity lymphodepletion and adoptive immunotherapy - How far can we go?. In: Nature Clinical Practice Oncology. 2006 ; Vol. 3, No. 12. pp. 668-681.
@article{aadf56a183a249a0a3b527a21bdd2c22,
title = "Increased intensity lymphodepletion and adoptive immunotherapy - How far can we go?",
abstract = "In a recent clinical trial involving patients with metastatic melanoma, immunosuppressive conditioning with fludarabine and cyclophosphamide resulted in a 50{\%} response rate in robust long-term persistence of adoptively transferred T cells. Experimental findings indicate that lymphodepletion prior to adoptive transfer of tumor-specific T lymphocytes plays a key role in enhancing treatment efficacy by eliminating regulatory T cells and competing elements of the immune system ('cytokine sinks'). Newly emerging animal data suggest that more profound lymphoablative conditioning with autologous hematopoetic stem-cell rescue might further enhance treatment results. Here we review recent advances in adoptive immunotherapy of solid tumors and discuss the rationale for lymphodepleting conditioning. We also address safety issues associated with translating experimental animal results of total lymphoid ablation into clinical practice.",
author = "Pawel Muranski and Andrea Boni and Claudia Wrzesinski and Citrin, {Deborah E.} and Rosenberg, {Steven A.} and Richard Childs and Restifo, {Nicholas P.}",
year = "2006",
month = "12",
doi = "10.1038/ncponc0666",
language = "English (US)",
volume = "3",
pages = "668--681",
journal = "Nature Clinical Practice Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - Increased intensity lymphodepletion and adoptive immunotherapy - How far can we go?

AU - Muranski, Pawel

AU - Boni, Andrea

AU - Wrzesinski, Claudia

AU - Citrin, Deborah E.

AU - Rosenberg, Steven A.

AU - Childs, Richard

AU - Restifo, Nicholas P.

PY - 2006/12

Y1 - 2006/12

N2 - In a recent clinical trial involving patients with metastatic melanoma, immunosuppressive conditioning with fludarabine and cyclophosphamide resulted in a 50% response rate in robust long-term persistence of adoptively transferred T cells. Experimental findings indicate that lymphodepletion prior to adoptive transfer of tumor-specific T lymphocytes plays a key role in enhancing treatment efficacy by eliminating regulatory T cells and competing elements of the immune system ('cytokine sinks'). Newly emerging animal data suggest that more profound lymphoablative conditioning with autologous hematopoetic stem-cell rescue might further enhance treatment results. Here we review recent advances in adoptive immunotherapy of solid tumors and discuss the rationale for lymphodepleting conditioning. We also address safety issues associated with translating experimental animal results of total lymphoid ablation into clinical practice.

AB - In a recent clinical trial involving patients with metastatic melanoma, immunosuppressive conditioning with fludarabine and cyclophosphamide resulted in a 50% response rate in robust long-term persistence of adoptively transferred T cells. Experimental findings indicate that lymphodepletion prior to adoptive transfer of tumor-specific T lymphocytes plays a key role in enhancing treatment efficacy by eliminating regulatory T cells and competing elements of the immune system ('cytokine sinks'). Newly emerging animal data suggest that more profound lymphoablative conditioning with autologous hematopoetic stem-cell rescue might further enhance treatment results. Here we review recent advances in adoptive immunotherapy of solid tumors and discuss the rationale for lymphodepleting conditioning. We also address safety issues associated with translating experimental animal results of total lymphoid ablation into clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=33751564865&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33751564865&partnerID=8YFLogxK

U2 - 10.1038/ncponc0666

DO - 10.1038/ncponc0666

M3 - Article

C2 - 17139318

AN - SCOPUS:33751564865

VL - 3

SP - 668

EP - 681

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1759-4774

IS - 12

ER -